164 related articles for article (PubMed ID: 15102606)
21. HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.
Wee EG; Ondondo B; Berglund P; Archer J; McMichael AJ; Baltimore D; Ter Meulen JH; Hanke T
Mol Ther; 2017 Feb; 25(2):494-503. PubMed ID: 28153096
[TBL] [Abstract][Full Text] [Related]
22. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
[TBL] [Abstract][Full Text] [Related]
23. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
24. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
25. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss B
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11341-8. PubMed ID: 8876137
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapeutic strategies for cancer using poxvirus vectors.
Paoletti E; Tartaglia J; Cox WI
Ann N Y Acad Sci; 1993 Aug; 690():292-300. PubMed ID: 8368744
[No Abstract] [Full Text] [Related]
27. Poxvirus vectors: cytoplasmic expression of transferred genes.
Moss B
Curr Opin Genet Dev; 1993 Feb; 3(1):86-90. PubMed ID: 8453278
[TBL] [Abstract][Full Text] [Related]
28. Genetic vaccination for the active immunotherapy of cancer.
Bronte V
Curr Gene Ther; 2001 May; 1(1):53-100. PubMed ID: 12109138
[TBL] [Abstract][Full Text] [Related]
29. Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.
Di Pilato M; Mejías-Pérez E; Sorzano COS; Esteban M
J Virol; 2017 Jul; 91(13):. PubMed ID: 28424281
[TBL] [Abstract][Full Text] [Related]
30. Enhancing poxvirus vectors vaccine immunogenicity.
García-Arriaza J; Esteban M
Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
[TBL] [Abstract][Full Text] [Related]
31. Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.
Vacas-Córdoba E; Climent N; De La Mata FJ; Plana M; Gómez R; Pion M; García F; Muñoz-Fernández MÁ
Nanomedicine (Lond); 2014 Dec; 9(17):2683-702. PubMed ID: 25529571
[TBL] [Abstract][Full Text] [Related]
32. Vaccinia and other poxvirus expression vectors.
Moss B
Curr Opin Biotechnol; 1992 Oct; 3(5):518-22. PubMed ID: 1368937
[TBL] [Abstract][Full Text] [Related]
33. Innate immune recognition of poxviral vaccine vectors.
Lousberg EL; Diener KR; Brown MP; Hayball JD
Expert Rev Vaccines; 2011 Oct; 10(10):1435-49. PubMed ID: 21988308
[TBL] [Abstract][Full Text] [Related]
34. The uses of poxviruses as vectors.
Vanderplasschen A; Pastoret PP
Curr Gene Ther; 2003 Dec; 3(6):583-95. PubMed ID: 14683453
[TBL] [Abstract][Full Text] [Related]
35. Poxvirus Safety Analysis in the Pregnant Mouse Model, Vaccinia, and Raccoonpox Viruses.
Roper RL
Methods Mol Biol; 2017; 1581():121-129. PubMed ID: 28374246
[TBL] [Abstract][Full Text] [Related]
36. Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.
Jackson SS; Ilyinskii P; Philippon V; Gritz L; Yafal AG; Zinnack K; Beaudry KR; Manson KH; Lifton MA; Kuroda MJ; Letvin NL; Mazzara GP; Panicali DL
J Virol; 2005 May; 79(10):6554-9. PubMed ID: 15858042
[TBL] [Abstract][Full Text] [Related]
37. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
38. The basis for HIV immunotherapeutic vaccines.
Peters BS
Vaccine; 2001 Dec; 20(5-6):688-705. PubMed ID: 11738732
[TBL] [Abstract][Full Text] [Related]
39. Adenovirus vector-based vaccines for human immunodeficiency virus type 1.
Barouch DH; Nabel GJ
Hum Gene Ther; 2005 Feb; 16(2):149-56. PubMed ID: 15761255
[TBL] [Abstract][Full Text] [Related]
40. Poxviruses as expression vectors.
Carroll MW; Moss B
Curr Opin Biotechnol; 1997 Oct; 8(5):573-7. PubMed ID: 9353230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
